All In Biotech

Investigational drug · Phase 3

[18F]-APN-1607

Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Alzheimer's Disease, Subjects With Mild Cognitive Impairment (MCI) of AD, Alzheimer's Disease (AD) Dementia.

Phase 3

Last checked: Nov 20, 2026Latest source record: Aug 17, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 3

Industry-sponsored trials

Phase 2 and 3 trials

2

2 still active

All registered trials

n/a

Any phase or sponsor naming "[18F]-APN-1607"

First trial start

2026

Jan 22, 2026

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "[18F]-APN-1607", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Alzheimer's Disease
  • Subjects With Mild Cognitive Impairment (MCI) of AD, Alzheimer's Disease (AD) Dementia

Approved drugs for the same conditions: Alzheimer's disease · Neurology

Largest trials

Live from ClinicalTrials.gov: studies naming "[18F]-APN-1607" as an intervention, largest first.

All trials
ClinicalTrials.gov returned an error (400). The numbers below may be missing or incomplete.

Newest research

PubMed records naming it or its code names, newest first.

All 6 on PubMed

Also in development for Alzheimer's Disease

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.